Table 4.

DFS and OS of High-Dose CAF Patients Subdivided by ErbB-2 Status at Median Follow-Up of 11 Years

ErbB-2 Status	DFS			OS
		%	95% CI	%	95% CI
All ErbB-2 high	62	52 to 73	71	61 to 81
All ErbB-2 low	49	42 to 56	56	49 to 63
ErbB-2 high/P-ErbB-2−	59	46 to 76	69	56 to 85
ErbB-2 high/P-ErbB-2+	60	44 to 80	66	51 to 86
ErbB-2 low/P-ErbB-2−	51	45 to 59	58	52 to 66
ErbB-2 low/P-ErbB-2+	25	6 to 83	42	16 to 100
All P-ErbB-2 negative	53	47 to 60	60	54 to 67
All P-ErbB-2 positive	52	39 to 71	60	46 to 80
FISH positive	48	38 to 60	51	41 to 63
FISH negative	53	48 to 59	61	56 to 66

Abbreviations: DFS, disease-free survival; OS, overall survival; CAF, cyclophosphamide, doxorubicin, and fluorouracil.